MX2022015525A - Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. - Google Patents
Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.Info
- Publication number
- MX2022015525A MX2022015525A MX2022015525A MX2022015525A MX2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A MX 2022015525 A MX2022015525 A MX 2022015525A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclohexyl
- ylsulfanyl
- ureido
- thiazol
- propoxy
- Prior art date
Links
- HPGJSAAUJGAMLV-UHFFFAOYSA-N 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid Chemical compound C1CC(OCCC)CCC1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-UHFFFAOYSA-N 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan en este documento sales de sodio, piperazina y clorhidrato o co-cristales de ácido {2-[3-ciclohexil-3-(trans-4-pr opoxiciclohexil)ureido]tiazol-5-ilsulfanil}acético ("Compuesto 1").
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063035996P | 2020-06-08 | 2020-06-08 | |
PCT/US2021/036084 WO2021252311A1 (en) | 2020-06-08 | 2021-06-07 | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015525A true MX2022015525A (es) | 2023-03-23 |
Family
ID=78845832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022015525A MX2022015525A (es) | 2020-06-08 | 2021-06-07 | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230219909A1 (es) |
EP (1) | EP4161640A4 (es) |
JP (1) | JP2023530786A (es) |
KR (1) | KR20230048502A (es) |
CN (1) | CN116194442A (es) |
AU (1) | AU2021289309A1 (es) |
CA (1) | CA3181722A1 (es) |
MX (1) | MX2022015525A (es) |
WO (1) | WO2021252311A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005203930C1 (en) * | 2004-01-06 | 2012-02-23 | Vtv Therapeutics Llc | Heteroaryl-ureas and their use as glucokinase activators |
MX347372B (es) * | 2010-05-26 | 2017-04-25 | Vtv Therapeutics Llc | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. |
JP6234443B2 (ja) * | 2012-05-17 | 2017-11-22 | ブイティーブイ・セラピューティクス・エルエルシー | 糖尿病治療のためのグルコキナーゼ活性化因子組成物 |
AU2014226292B2 (en) * | 2013-03-04 | 2018-10-04 | Vtv Therapeutics Llc | Solid compositions comprising a glucokinase activator and methods of making and using the same |
WO2014137797A2 (en) * | 2013-03-04 | 2014-09-12 | Transtech Pharma, Llc | Stable glucokinase activator compositions |
MX2019007119A (es) * | 2016-12-15 | 2020-01-21 | Hua Medicine (Shanghai) Ltd | Preparado oral del activador de glucocinasa y preparacion del mismo. |
-
2021
- 2021-06-07 KR KR1020237000610A patent/KR20230048502A/ko unknown
- 2021-06-07 MX MX2022015525A patent/MX2022015525A/es unknown
- 2021-06-07 EP EP21822587.8A patent/EP4161640A4/en active Pending
- 2021-06-07 AU AU2021289309A patent/AU2021289309A1/en active Pending
- 2021-06-07 JP JP2023519157A patent/JP2023530786A/ja active Pending
- 2021-06-07 CA CA3181722A patent/CA3181722A1/en active Pending
- 2021-06-07 CN CN202180056620.5A patent/CN116194442A/zh active Pending
- 2021-06-07 WO PCT/US2021/036084 patent/WO2021252311A1/en unknown
- 2021-06-07 US US18/000,907 patent/US20230219909A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021289309A1 (en) | 2023-01-19 |
CA3181722A1 (en) | 2021-12-16 |
WO2021252311A1 (en) | 2021-12-16 |
US20230219909A1 (en) | 2023-07-13 |
CN116194442A (zh) | 2023-05-30 |
EP4161640A4 (en) | 2024-01-17 |
JP2023530786A (ja) | 2023-07-19 |
EP4161640A1 (en) | 2023-04-12 |
KR20230048502A (ko) | 2023-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022015525A (es) | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. | |
TN2009000459A1 (en) | Metabolites of (thio) carbamoyl-cyclohexane derivatives | |
NO155805C (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter. | |
PT998473E (pt) | Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao | |
DE60234028D1 (de) | Hydantion-derivate als hemmer von matrix-metalloproteinasen | |
DE602005013990D1 (de) | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften | |
EA200971046A1 (ru) | Новые соли пиперазина в качестве d/d-антагонистов | |
CY1105362T1 (el) | Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα | |
DK2164492T3 (da) | Trans-4-{2-[4-(2,3-dichlorphenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoylcyclohexylamin til behandling af skizofreni | |
CY1110358T1 (el) | Υποκατεστημενα παραγωγα προπενυλ πιπεραζινης ως νεοι αναστολεις της αποακετυλασης ιστονης | |
MX2022016515A (es) | Nuevo inhibidor de la secrecion de acido y uso del mismo. | |
MY148955A (en) | Carbamoly-cyclohexanes for treating acute mania | |
MX2022001958A (es) | Sal. | |
AR057961A1 (es) | Derivados de pirrolopirimidinas con actividad inhibitoria de receptor de tirosina quinasa. composiciones farmaceuticas. | |
BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação | |
CL2023001367A1 (es) | Inhibidores de btk | |
PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 | |
UY38345A (es) | Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g | |
MX2021015214A (es) | Compuestos para tratar enfermedad respiratoria. | |
MX2021010906A (es) | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas. | |
HRP20050815A2 (en) | 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound | |
GB1417402A (en) | Pharmacologically active anilinobenzothiazoles | |
MX2023003245A (es) | Derivados de amina novedosos. | |
MX2022002187A (es) | Composicion de amida peptidica y metodo para su preparacion. | |
HUP0105176A2 (hu) | Benzolszulfonamidszármazékok és alkalmazásuk |